ArticlePharmacoEconomics2022
Estimating an EQ-5D-Y-3L Value Set for China.
Article in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Measurement Properties of the EQ-5D Instruments in Children and Adolescents: A Systematic Review.Applied health economics and health policy · 2025Pooled it
- The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment.PharmacoEconomics · 2026Trial
- Justifying and Classifying Adults' Roles in Child Health State Valuation: A Novel Taxonomy.PharmacoEconomics · 2026Review
- Validation of proxy-reported EQ-5D-Y-3L in younger children with spinal muscular atrophy: age-related differences in performance.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Psychometric properties comparison of EQ-5D-Y-3L and CHU-9D in children with adenoid hypertrophy.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Mapping the NEI-VFQ-25 scores to the EQ-5D-Y-3L and CHU-9D utility values among adolescents with myopia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Impact of Allergen-Specific Subcutaneous Immunotherapy on 12-Month Health-Related Quality of Life in Children and Their Parental Caregivers.Allergy, asthma & immunology research · 2026Article
- Valuation of the EQ-5D-Y-5L Using DCE Methods That Account for Nonlinear Time Preferences.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Value set of EQ-5D-Y-3L for Hong Kong.Health and quality of life outcomes · 2026Article
- Self-esteem patterns and the associations with health-related quality of life, self-rated health and lifestyle behaviour among junior high school students: a latent class analysis.BMC psychology · 2026Article
- Psychometric properties comparison of EQ-5D-Y-3L and CHU9D in children and adolescents across different BMI classifications in Jiangsu, China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Measuring health spillover effects in household members of adolescents and elderly individuals with health issues in China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Health-related quality of life and its influencing factors in Chinese patients with phenylketonuria.Frontiers in pediatrics · 2026Article
- EQ-5D-Y-3L population norms for children in Mainland China derived from a national survey 2023-2024.Health and quality of life outcomes · 2025Article
- Developing an EQ-5D-5L Value Set for Singapore.PharmacoEconomics · 2025Article
- Assessing the economic burden and health-related quality of life in chinese patients with fibrodysplasia ossificans progressiva: a questionnaire survey analysis.Orphanet journal of rare diseases · 2025Article
- An Australian Value Set for the EQ-5D-Y-3L.Health and quality of life outcomes · 2025Article
- Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?PharmacoEconomics - open · 2025Article
- Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe standard EQ-5D-Y-3L valuation protocol applies DCE data as the primary preference source to model the relative importance of dimensions while cTTO data served to anchor the DCE coefficients onto the QALY scale. This study aims to estimate an EQ-5D-Y-3L value set for China following this protocol, but with a larger cTTO design to better understand the role of cTTO data in estimating EQ-5D-Y-3L value sets.
methodsIn total, 150 choice sets and 28 EQ-5D-Y-3L health states were valued using DCE and cTTO methods with two independent samples, respectively. General public from 14 different regions were recruited using quota sampling method to achieve representativeness. We compared two modelling strategies: (1) fit the DCE data with mixed logit model with correlated coefficients and a subsequent mapping procedure for anchoring; (2) fit the DCE and TTO data jointly in a hybrid model. Two evaluation criteria (1) coefficient significance and monotonicity; (2) prediction accuracy of the observed cTTO values were used to select the value set.
resultsIn total, 1476 individuals participated in the study, with 1058 participated the DCE interview and 418 participated the cTTO interview. The highest mean TTO value was 0.924 for state 11112 and the lowest mean TTO value was - 0.088 for state 33333. The hybrid model with an A3 term performed the best and was selected as the value set. DISCUSSION: Following the international protocol and using a larger cTTO design, this study established the EQ-5D-Y-3L value set using a hybrid model for China. Future EQ-5D-Y-3L valuation study could consider using a larger cTTO design for estimating the value set.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.